Bio-Rad Laboratories, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Norman D. Schwartz
- Full Time Employees
- 7,450
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 1000 Alfred Nobel Drive Hercules CA United States of America 94547
- IPO Date
- Feb 27, 1980
- CIK
- 0000012208
- Website
- bio-rad.com
- Similar Companies
- Business
- Bio-Rad Laboratories, Inc. is a global leader in the development and manufacture of life science research and clinical diagnostics products. Founded in 1952 and headquartered in Hercules, California, the company operates internationally across the United States, Europe, Asia, Canada, and Latin America. Bio-Rad's core products span life science research instruments and consumables, including chromatography resins and media, flow cytometry antibodies, Droplet Digital PCR (ddPCR) platforms and reagents, as well as advanced digital PCR solutions designed for genomic research and applied sciences. In clinical diagnostics, Bio-Rad offers systems and assays for autoimmune testing, infectious disease detection, diabetes monitoring, blood typing and screening, cardiac assessment controls, molecular quality controls, veterinary diagnostics, and water quality testing. The company serves a broad range of customers from research institutions to clinical, hospital, and veterinary laboratories. Recent major changes include the acquisition of Stilla Technologies in the second quarter of 2025, which enhances Bio-Rad's digital PCR portfolio by integrating Stilla’s QX700 series instruments with Bio-Rad's existing QX Continuum system, thereby accelerating innovation in molecular diagnostics and precision medicine. In 2024, Bio-Rad also completed the acquisition of Saber Bio, a company focused on droplet technology for antibody discovery, aligning with its expansion in cell biology products. Additionally, Bio-Rad has launched new products such as the StarBright dyes for flow cytometry to improve multiplexing capabilities and kits for precise mutation detection in oncology applications leveraging its ddPCR technology. These developments support the company’s strategic focus on enhancing automation, throughput, and the sensitivity of its diagnostics platforms, further positioning it as a key player in advancing life science research and clinical diagnostic solutions. Bio-Rad continues to invest in transformative technologies such as Droplet Digital PCR for non-invasive cancer screening and gene therapy production, supported by ongoing product development and expansion of its assay portfolio. The company’s broad product offering includes instruments, software, reagents, and specialized consumables designed to support applications in cell biology, gene expression, protein purification, drug discovery, infectious diseases, and transfusion medicine. With a commitment to innovation and global healthcare advancement, Bio-Rad maintains a strong presence in both the life sciences and clinical diagnostics markets, driving growth through strategic acquisitions, product launches, and enhanced service offerings.
BIO-key's Bottom Line Improves 51% on 13% Rise in Q2 Revenues Reflecting Strength with Government, Defense, and Financial Sector Customers Globally; Call Tomorrow at 10am ET
First Trust Advisors LP Has $424,000 Position in Bio-Rad Laboratories, Inc. $BIO
BIO GREEN MED SOLUTION REPORTS SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
Portuguese National Security Agency Selects BIO-key and Visualforma to Strengthen Identity Security
Advanced Authentication Solutions Provider BIO-key Hosts Q2 Investor Call Friday, August 14th at 10am ET
BIO-key and Maktabi Tech Partner to Advance Identity Security Across Saudi Arabia's Education Sector
Amundi Has $10.81 Million Holdings in Bio-Rad Laboratories, Inc. $BIO
Bio-Rad Laboratories Q2 Earnings Call Highlights
Bio-Rad Laboratories, Inc. (BIO) Q2 2026 Earnings Call Transcript
Bio-Rad Laboratories (BIO) Beats Q2 Earnings Estimates
Bio-Rad Reports Second-Quarter 2026 Financial Results
Bio-Rad Laboratories Inc (BIO) Stock Up 4.6% but GF Value Says Overvalued -- GF Score: 72/100
Central Bank of Jordan Selects BIO-key for National Biometric Authentication Initiative
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
Bio-Rad Laboratories Inc (BIO) Stock Up 3.4% and Still Undervalued -- GF Score: 72/100
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
Assetmark Inc. Raises Stock Holdings in Bio-Rad Laboratories, Inc. $BIO
Noveris Health Sciences Joins the Biotechnology Innovation Organization (BIO)